Symmetry Partners, LLC Vertex Pharmaceuticals Inc Transaction History

Symmetry Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 11, 2024	SELL	$392.81 - $485.53 $370,419 - $457,854	-943 Reduced 32.82%	1,930 $905,000
Q3 2023 Oct 10, 2023	SELL	$338.18 - $362.46 $70,341 - $75,391	-208 Reduced 6.75%	2,873 $999,000
Q1 2023 Apr 03, 2023	BUY	$283.23 - $323.1 $267,085 - $304,683	943 Added 44.11%	3,081 $971,000
Q3 2022 Oct 03, 2022	BUY	$273.83 - $305.53 $98,031 - $109,379	358 Added 20.11%	2,138 $619,000
Q2 2022 Jul 11, 2022	BUY	$234.96 - $292.55 $418,228 - $520,739	1,780 New	1,780 $502,000
Q4 2021 Jan 11, 2022	SELL	$177.01 - $223.45 $218,253 - $275,513	-1,233 Closed	0 $0
Q2 2021 Jul 07, 2021	BUY	$187.49 - $221.1 $231,175 - $272,616	1,233 New	1,233 $249,000
Q1 2021 May 03, 2021	SELL	$207.02 - $241.31 $388,576 - $452,938	-1,877 Closed	0 $0
Q4 2020 Feb 18, 2021	SELL	$207.01 - $276.09 $16,353 - $21,811	-79 Reduced 4.04%	1,877 $444,000
Q3 2020 Nov 03, 2020	SELL	$255.65 - $303.1 $23,264 - $27,582	-91 Reduced 4.45%	1,956 $532,000
Q2 2020 Jul 20, 2020	BUY	$225.48 - $295.8 $461,557 - $605,502	2,047 New	2,047 $594,000

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Symmetry Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Symmetry Partners, LLC with notifications on news.